SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced ...
Shares of China’s Hansoh Pharmaceutical edged up 2% to HK$36.50 as it announced a license agreement with Roche for HS-20110, ...
Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024. During the first half ...
Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.
Chinese biotech Kelun-Biotech (HKEX: 6990) has gained approval from the National Medical Products Administration for ...
Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event ...
Public interest has been growing towards the typhoid vaccine and there is no hesitation about it in Rajshahi. In the initial ...
Public interest has been growing towards the typhoid vaccine and there is no hesitation to it in Rajshahi. In the initial ...
A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China’s Hansoh ...
Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...
Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback